Bioimpedance-derived body composition parameters predict mortality and dose-limiting toxicity: the multicenter...

Area of Science:

• Oncology
• Body Composition Analysis
• Clinical Nutrition

Background:

• Lean body mass loss is common in cancer patients, negatively impacting treatment tolerance and survival.
• Bioelectrical impedance analysis (BIA) is a widely used method for assessing body composition.
• The predictive value of BIA parameters for mortality and dose-limiting toxicity (DLT) in cancer patients requires further investigation.

Purpose of the Study:

• To evaluate the utility of BIA-derived body composition parameters in predicting 1-year mortality in cancer patients.
• To assess the association between BIA parameters and dose-limiting toxicity (DLT) in cancer patients receiving primary systemic treatment.
• To explore the clinical implications of BIA in the management of cancer patients.

Main Methods:

• A prospective, multicenter observational study involving 640 adult patients with solid tumors undergoing primary systemic treatment.
• Collection of BIA-derived parameters including phase angle (PhA), standardized PhA (SPA), and Nutrigram®.
• Primary outcome: 1-year mortality. Key secondary outcome: DLT, defined as severe toxicity necessitating treatment modification.

Main Results:

• All BIA parameters (SPA, PhA, Nutrigram®) were independently associated with increased 1-year mortality.
• SPA demonstrated a significant association with mortality (HR=1.59, P<0.001).
• BIA parameters, particularly SPA (OR=6.37, P<0.001), were significantly associated with the occurrence of DLT.

Conclusions:

• BIA-derived body composition parameters are independent predictors of both mortality and DLT in cancer patients.
• These findings suggest BIA can enhance clinical assessment and potentially guide treatment strategies.
• The study highlights the importance of body composition assessment in optimizing cancer patient care.